Drug interactions
Encorafenib + Lapatinib
Severity: Major
Encorafenib and Lapatinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both drugs can prolong the QT interval, so combining them adds to the risk of ventricular arrhythmia. The risk increases with electrolyte disturbance or heart disease.
What this interaction means in plain words
Encorafenib and Lapatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Encorafenib belongs to Oncology; Lapatinib belongs to Oncology.
Why it happens
Additive pharmacodynamic QT prolongation.
What to do
Monitor ECG and electrolytes at baseline and periodically during treatment. Correct hypokalemia and hypomagnesemia, and interrupt or reduce a drug if the QTc becomes markedly prolonged.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Lapatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lapatinib
- Dofetilide + Lapatinib Contraindicated
- Ibutilide + Lapatinib Contraindicated
- Lapatinib + Pimozide Contraindicated
- Lapatinib + Saquinavir Contraindicated
- Lapatinib + Thioridazine Contraindicated
- Adagrasib + Lapatinib Major
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Lapatinib?
MediHelp rates the interaction as major. Encorafenib and Lapatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both drugs can prolong the QT interval, so combining them adds to the risk of ventricular arrhythmia. The risk increases with electrolyte disturbance or heart disease.
How serious is the interaction between Encorafenib and Lapatinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor ECG and electrolytes at baseline and periodically during treatment. Correct hypokalemia and hypomagnesemia, and interrupt or reduce a drug if the QTc becomes markedly prolonged.
What other medicines interact with Lapatinib?
MediHelp also lists interactions of Lapatinib with, for example, Dofetilide, Ibutilide, Pimozide. The full list is on the Lapatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
